Defendants in Delaware’s Zantac litigation have asked the state Supreme Court to review a Superior Court ruling that allowed testimony from plaintiffs’ experts, by claiming that the decision placed the state’s Daubert standards at odds with those of federal courts and previous decisions in the jurisdiction.

GlaxoSmithKline, Pfizer, Sanofi and Boehringer Ingelheim, represented by lead national counsel from Dechert, Williams & Connolly, DLA Piper, and King & Spalding, respectively, filed an application for interlocutory review on June 10. And in the application, they argued that, by allowing Superior Court Judge Vivian Medinilla’s May 31 order to stand, it could result in mass tort plaintiffs flocking to Delaware.